UNSPSC 51191921: Nicorandil

This classification denotes a vasodilating agent with the molecular formula C8H9N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 260456HAM0, chemically known as 3-pyridinecarboxamide, n-(2-(nitroxy)ethyl)- but generally known as nicorandil, which bears US NIH Compound Identifier 47528. European Medicines Agency schedules Nicorandil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09244MIG.

UNSPSC 51191921 Nicorandil is a Commodity code that in practice captures chemical supply and pharmaceutical procurement by state and local government agencies, though the recent opportunities block shows little activity directly matching the nominal product. The City of Meriden's IFB for sodium bisulfite chemical supply to its Water Pollution Control Facility (due July 29, 2026) and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026) illustrate the breadth of what state and local buyers tag under this code — from industrial water-treatment chemicals to broad pharmaceutical inventory supply. Issuing bodies include municipal utilities, state cooperative purchasing vehicles administering agreements across multiple jurisdictions, and health and human services facilities. The scope typically encompasses chemical commodities and pharmaceuticals required for regulatory compliance, facility operations, or healthcare delivery, with pricing evaluated on unit-cost or competitive pricing bases and contractors required to maintain substantial general liability and workers' compensation insurance.

Geographic activity is concentrated in the Northeast and Upper Midwest, with recent solicitations from Connecticut and Minnesota. The City of Meriden's sodium bisulfite procurement is a straightforward IFB with performance and payment bonds required and a deadline of July 29, 2026. The MMCAP RFP represents larger-scale cooperative purchasing spanning Minnesota and Oregon, seeking manufacturers of generic pharmaceuticals and OTC products through authorized wholesalers with an effective date of July 1, 2026; vendors must certify cGMP and DSCSA compliance, maintain relationships with at least two of three specified wholesalers, and accept a 3 percent administrative fee on all contract purchases. Neither solicitation identifies state or local set-aside designations.